Holen Sie sich die Stockscreener-App
23.57
0.23%
0.1024
Schlusskurs vom Vortag:
$23.47
Offen:
$23.59
24-Stunden-Volumen:
71,744
Relative Volume:
0.08
Marktkapitalisierung:
$1.10B
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-6.423
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
+3.59%
1M Leistung:
+3.63%
6M Leistung:
+70.35%
1J Leistung:
+113.09%
1-Tages-Spanne:
$23.20
$24.10
1-Wochen-Bereich:
$20.99
$24.10
52-Wochen-Spanne:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Vergleichen Sie URGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
23.59 | 1.10B | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Why UroGen Pharma Ltd. (UR8) stock attracts HNW investorsGlobal Markets & Technical Pattern Based Buy Signals - ulpravda.ru
Is UroGen Pharma Ltd. stock oversold or undervalued2025 Market Outlook & High Win Rate Trade Tips - ulpravda.ru
What momentum indicators show for UroGen Pharma Ltd. stock2025 Key Highlights & Advanced Technical Analysis Signals - ulpravda.ru
Why UroGen Pharma Ltd. stock appeals to analystsJuly 2025 Movers & Weekly High Return Forecasts - ulpravda.ru
Will UroGen Pharma Ltd. stock benefit from infrastructure spendingJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - ulpravda.ru
Will UroGen Pharma Ltd. stock see insider buyingFundamental Strength Indicators & Free Unlock Rapid Growth Potential - ulpravda.ru
Multiple Insiders Sold UroGen Pharma Shares Presenting Weak Signs For Investors - simplywall.st
How UroGen Pharma Ltd. (UR8) stock trades in high volatility2026 world cup usa national team round of 32 playmakers possession football expert forecast preview - ulpravda.ru
UroGen Pharma says permanent J Code for ZUSDURI now in effect - Yahoo Finance
Urogen Pharma (NASDAQ:URGN) Shares Down 6.5%What's Next? - MarketBeat
UroGen Pharma Ltd. Announces That Adult Patients Living with Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) Now Have Improved Access to an Important Therapy - MarketScreener
UroGen Pharma (URGN) Analyst Ratings Remain Steady with Buy Rati - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy - GlobeNewswire
The Truth About UroGen Pharma (URGN): Is This Tiny Cancer Stock the Next Viral Game-Changer or a Tot - AD HOC NEWS
What analysts say about UroGen Pharma Ltd stockMarket Timing Techniques & Free High Velocity Capital Growth - earlytimes.in
The Technical Signals Behind (URGN) That Institutions Follow - Stock Traders Daily
URGN: Small-Cap Biotech On A Knife Edge As Traders Weigh Risk, Cash And Uro-Oncology Data - AD HOC NEWS
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - AOL.com
Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance
What drives UroGen Pharma Ltd stock priceBreakout Stock Watch & Free Exceptional Market Positioning - earlytimes.in
Chemo Pharma Laboratories Limited Stock Fails to Break Resistance Traders ReactMarket Liquidity Analysis & Low Risk Capital Gains - bollywoodhelpline.com
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally - The Motley Fool
What analysts say about UroGen Pharma Ltd UR8 stockGlobal Trade Effects & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Trading Systems Reacting to (URGN) Volatility - news.stocktradersdaily.com
Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC - MarketBeat
Volume Report: What valuation multiples suggest for UroGen Pharma Ltd. stock2025 Market WrapUp & Long Hold Capital Preservation Tips - Улправда
Can UroGen Pharma Ltd. stock surprise with earnings upsideJuly 2025 Levels & Real-Time Market Trend Scan - Улправда
Can UroGen Pharma Ltd. stock deliver sustainable ROEPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - Улправда
US Stocks Recap: Will UroGen Pharma Ltd. (UR8) stock benefit from Fed rate cuts2025 Fundamental Recap & Intraday High Probability Setup Alerts - Улправда
What valuation multiples suggest for UroGen Pharma Ltd. stockJuly 2025 Trade Ideas & Daily Stock Trend Reports - Улправда
FOMO Trade: Why UroGen Pharma Ltd. stock appeals to analystsPortfolio Value Summary & Risk Controlled Stock Alerts - Улправда
Urogen Pharma Target of Unusually Large Options Trading (NASDAQ:URGN) - MarketBeat
Q2 2025 Urogen Pharma Ltd Earnings Call Transcript - GuruFocus
Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.4%Still a Buy? - MarketBeat
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Acorn Capital Advisors LLC Has $17.26 Million Stock Holdings in Urogen Pharma $URGN - MarketBeat
Avoiding Lag: Real-Time Signals in (URGN) Movement - news.stocktradersdaily.com
Earnings Recap: Is UroGen Pharma Ltd stock trading at a premium valuation2025 Earnings Surprises & Low Risk Profit Maximizing Plans - moha.gov.vn
Menora Mivtachim Holdings LTD. Reduces Holdings in Urogen Pharma $URGN - MarketBeat
Urogen Pharma $URGN Shares Purchased by Diadema Partners LP - MarketBeat
Urogen Pharma milestone: First patient treated with new cancer medication - Traders Union
Walleye Capital LLC Takes Position in Urogen Pharma $URGN - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma - The National Law Review
UroGen Pharma (URGN) Issues Stock Units to New Employees - GuruFocus
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected - simplywall.st
Panagora Asset Management Inc. Acquires 168,908 Shares of Urogen Pharma $URGN - MarketBeat
Is UroGen Pharma Ltd. (UR8) stock prepared for digital transition2025 Biggest Moves & Free Reliable Trade Execution Plans - Newser
What margin trends mean for UroGen Pharma Ltd. stockJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - Newser
Why UroGen Pharma Ltd. (UR8) stock signals breakout potentialJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - Newser
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):